1. 797PDLATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO). (23rd October 2018) Authors: Matsubara, N; Chi, K N; Ozguroglu, M; Rodriguez Antolin, A; Feyerabend, S; Fein, L; Alekseev, B Y; Sulur, G; Protheroe, A; Li, S; Mundle, S D; De Porre, P; Tran, N; Fazazi, K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 928TiPATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma. (23rd October 2018) Authors: Chowdhury, S; Feyerabend, S; Loriot, Y; Necchi, A; Gupta, S; Josephs, D H; Rodríguez-Vida, A; Srinivas, S; Zakharia, Y; Nepert, D; Wride, K; Thomas, D; Loehr, A; Simmons, A D; Grivas, P Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗